To be considered for a lead plaintiff role, a Bolt investor must file a motion in the U.S. District Court for the Northern District of California, no later than September 3, 2024. Please contact Edelson Lechtzin LLP to discuss your investment losses, at 844-696-7492 or by e-mail at [email protected]. You can also submit your trading information online HERE. Background on Bolt Biotherapeutics, Inc. focused on developing immunotherapies for cancer treatment, primarily through its "Boltbody" pipeline. The Bolt ...

[Click here for information about joining the class action] Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or c ...

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_i ...

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Willie Quinn - Incoming Chief Executive Officer Randy Schatzman - Outgoing Chief Executive Officer Edith Perez - Outgoing Chief Medical Officer Michael Alonso - Co-Founder of Bolt and Senior Vice President of Research Dawn Colburn - Senior Vice President of Clinical Development. Conference Call Participants Jeffrey La Rosa - Leerink Partners Stephen Willey - Stifel Michael Schmidt - Guggenh ...

| --- | --- | |--------------------------|-------------------------------------------------------------------------------------------------------| | | | | | BOLT BIOTHERAPEUTICS, INC. | | Date: May 14, 2024 | By: /s/ Randall C. Schatzman, Ph.D. | | | Randall C. Schatzman, Ph.D. Chief Executive Officer (Principal Executive Of icer) | | | | | Date: May 14, 2024 | By: /s/ William P. Quinn | | | William P. Quinn Chief Financial Officer (Principal Financial and Accounting Of icer) | 30 None. 27 Item 4. Mine Safe ...

Table of Contents Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production. In addition, our third-party manufacturers and suppliers are subject to FDA inspection from time to time. Failure by our third-party manufacturers and suppliers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidate may result in regulatory actions such as the issuance of FDA Form 4 ...

Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update – BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones – BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 "We made substantial progress advancing our two proprie ...

Item 1A. Risk Factors. None. 31 None. X X X X SIGNATURES The following table sets forth a summary of our cash flows for each of the periods indicated: License Agreements with Stanford University FORM 10-Q | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------|-----------------------------------------|-------|-----------|--------|-------------------------------------------------------|------------------|---------|----------- ...

The following table presents changes in the Company contract liability (in thousands): 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan In January 2021, the Company's board of directors adopted the 2021 Equity Incentive Plan (the "2021 Plan") and the Company's stockholders approved the 2021 Plan. The 2021 Plan authorized issuance of up to 8,075,000 shares of common stock and it became effective upon the execution of the underwriting agreement for the Company's IPO. In addition, the number of ...

Legal Proceedings 16 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan Performance and Service-Based Stock Options The following table summarizes the components of stock-based compensation expense recognized in the Company's statement of operations and comprehensive loss (in thousands): 17 The following table sets forth the computation of the Company's basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding, but subject to ...